Aytu Bioscience Company Profile (OTCMKTS:AYTU)

About Aytu Bioscience (OTCMKTS:AYTU)

Aytu Bioscience logoAytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women's sexual wellbeing and intimacy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:AYTU
  • CUSIP: N/A
  • Web: aytubio.com
Capitalization:
  • Market Cap: $5.57 million
  • Outstanding Shares: 13,836,000
Average Prices:
  • 50 Day Moving Avg: $0.57
  • 200 Day Moving Avg: $0.79
  • 52 Week Range: $0.32 - $4.04
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.30
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.32 million
  • Price / Sales: 1.46
  • Book Value: $0.62 per share
  • Price / Book: 0.56
Profitability:
  • EBIDTA: ($17,690,000.00)
  • Net Margins: -934.55%
  • Return on Equity: -243.90%
  • Return on Assets: -107.80%
Debt:
  • Current Ratio: 1.32%
  • Quick Ratio: 1.26%
Misc:
  • Average Volume: 19,722 shs.
  • Beta: 3.7
 
Frequently Asked Questions for Aytu Bioscience (OTCMKTS:AYTU)

What is Aytu Bioscience's stock symbol?

Aytu Bioscience trades on the OTCMKTS under the ticker symbol "AYTU."

How were Aytu Bioscience's earnings last quarter?

Aytu Bioscience, Inc. (OTCMKTS:AYTU) posted its quarterly earnings results on Thursday, May, 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.20. The business earned $0.89 million during the quarter, compared to analyst estimates of $1.08 million. Aytu Bioscience had a negative net margin of 934.55% and a negative return on equity of 243.90%. View Aytu Bioscience's Earnings History.

When will Aytu Bioscience make its next earnings announcement?

Aytu Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, August, 30th 2017. View Earnings Estimates for Aytu Bioscience.

Where is Aytu Bioscience's stock going? Where will Aytu Bioscience's stock price be in 2017?

3 brokers have issued 12-month target prices for Aytu Bioscience's stock. Their forecasts range from $3.00 to $9.00. On average, they anticipate Aytu Bioscience's share price to reach $6.00 in the next twelve months. View Analyst Ratings for Aytu Bioscience.

Who are some of Aytu Bioscience's key competitors?

Who are Aytu Bioscience's key executives?

Aytu Bioscience's management team includes the folowing people:

  • Joshua R. Disbrow, Chief Executive Officer, Director
  • Gregory A. Gould CPA, Chief Financial Officer, Treasurer, Secretary
  • Jarrett T. Disbrow, Chief Operating Officer
  • Michael Macaluso, Director
  • Gary V. Cantrell, Independent Director
  • Carl C. Dockery, Independent Director
  • John Donofrio Jr., Independent Director

How do I buy Aytu Bioscience stock?

Shares of Aytu Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aytu Bioscience's stock price today?

One share of Aytu Bioscience stock can currently be purchased for approximately $0.35.


MarketBeat Community Rating for Aytu Bioscience (OTCMKTS AYTU)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  19
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aytu Bioscience (OTCMKTS:AYTU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $6.00

Analysts' Ratings History for Aytu Bioscience (OTCMKTS:AYTU)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2017HC WainwrightSet Price TargetBuy$3.00View Rating Details
2/17/2017Taglich BrothersReiterated RatingSpeculative BuyView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$9.00View Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for Aytu Bioscience (OTCMKTS:AYTU)
Earnings by Quarter for Aytu Bioscience (OTCMKTS:AYTU)
Earnings History by Quarter for Aytu Bioscience (OTCMKTS AYTU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/30/2017($0.35)N/AView Earnings Details
5/11/2017Q3 2017($0.28)($0.48)$1.08 million$0.89 millionViewN/AView Earnings Details
2/9/201712/31/2016($0.52)($0.55)$1.11 million$0.79 millionViewN/AView Earnings Details
11/7/2016Q1 2017($0.84)($1.17)$1.20 million$0.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aytu Bioscience (OTCMKTS:AYTU)
Current Year EPS Consensus Estimate: $-2.23 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS

Dividends

Dividend History for Aytu Bioscience (OTCMKTS:AYTU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aytu Bioscience (OTCMKTS:AYTU)
Insider Ownership Percentage: 17.80%
Insider Trades by Quarter for Aytu Bioscience (OTCMKTS:AYTU)
Insider Trades by Quarter for Aytu Bioscience (OTCMKTS:AYTU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/20/2016Joshua R DisbrowCEOBuy153,846$0.65$99,999.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aytu Bioscience (OTCMKTS:AYTU)
Latest Headlines for Aytu Bioscience (OTCMKTS:AYTU)
Source:
DateHeadline
finance.yahoo.com logoAytu BioScience Expands MiOXSYS® Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe
finance.yahoo.com - July 13 at 5:05 PM
americanbankingnews.com logoAytu Bioscience, Inc. (AYTU) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 7 at 2:52 PM
finance.yahoo.com logoAytu BioScience Presents Clinical Findings for its MiOXSYS® System at 33rd Annual Meeting of the European Society of Human Reproduction and Embryology
finance.yahoo.com - July 5 at 4:53 PM
prnewswire.com logoMale Infertility Market is expected to reach USD 4.7 billion by 2025
www.prnewswire.com - June 20 at 4:25 PM
finance.yahoo.com logoAytu BioScience Announces the Appointment of Gregory A. Gould as Permanent Chief Financial Officer
finance.yahoo.com - June 19 at 10:09 AM
marketwatch.com logoMale Infertility Market Size Worth $4.7 Billion by 2025 | CAGR: 4.6%: Grand View Research, Inc.
www.marketwatch.com - May 29 at 7:19 AM
finance.yahoo.com logoAytu BioScience Presents New Research Findings for its Natesto® Testosterone Nasal Gel at 112th American Urological Association Annual Meeting
finance.yahoo.com - May 17 at 12:09 PM
finance.yahoo.com logoAytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 16, 2017
finance.yahoo.com - May 16 at 12:25 PM
finance.yahoo.com logoAytu BioScience Presents New Research Findings for its MiOXSYS® System at 112th American Urological Association Annual Meeting
finance.yahoo.com - May 15 at 8:27 AM
seekingalpha.com logoAytu BioScience misses by $0.11, misses on revenue
seekingalpha.com - May 12 at 9:39 PM
americanbankingnews.com logoAytu Bioscience Inc (AYTU) Announces Earnings Results, Misses Expectations By $0.20 EPS
www.americanbankingnews.com - May 12 at 11:26 AM
finance.yahoo.com logoAytu BioScience Provides Third Quarter Fiscal 2017 Business Update
finance.yahoo.com - May 11 at 4:18 PM
finance.yahoo.com logoAytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera® Female Personal Care Device
finance.yahoo.com - May 9 at 8:59 AM
finance.yahoo.com logoAytu BioScience to Provide Fiscal Third Quarter 2017 Business Update
finance.yahoo.com - May 3 at 12:23 PM
finance.yahoo.com logoAytu BioScience Presents Latest Clinical Findings for Natesto® at ENDO 2017, the National Endocrine Society's Annual Scientific Meeting
finance.yahoo.com - April 7 at 8:18 AM
bizjournals.com logoAytu BioScience Announces Divestiture of Primsol® to Allegis Holdings
www.bizjournals.com - April 3 at 4:11 PM
biz.yahoo.com logoAYTU BIOSCIENCE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - March 17 at 4:26 PM
capitalcube.com logoAytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q2, 2017 By the Numbers : March 16, 2017
us.rd.yahoo.com - March 16 at 5:17 PM
finance.yahoo.com logoAytu BioScience Announces Peer-Reviewed Publication of Fourth Clinical Study Demonstrating the Utility of MiOXSYS® in the Assessment of Male Infertility
finance.yahoo.com - March 14 at 3:41 PM
finance.yahoo.com logoAytu BioScience Completes Successful Warrant Tender Offer and Receives $2.2 Million from Exercise of Warrants
finance.yahoo.com - March 1 at 3:46 PM
biz.yahoo.com logoAYTU BIOSCIENCE, INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 1 at 3:46 PM
finance.yahoo.com logoAytu BioScience May Lead the Way in Low T
finance.yahoo.com - February 28 at 11:40 AM
finance.yahoo.com logoAytu BioScience Announces Expansion of U.S. Sales Team to Support Increasing Growth of Natesto Prescriptions and Revenues
finance.yahoo.com - February 22 at 11:53 AM
finance.yahoo.com logoTaglich Brothers Initiates Coverage on Aytu Bioscience, Inc.
finance.yahoo.com - February 21 at 10:55 AM
us.rd.yahoo.com logoAytu BioScience Provides Second Quarter Fiscal 2017 Business Update and Financial Results
us.rd.yahoo.com - February 9 at 8:55 PM
biz.yahoo.com logoQ2 2017 Aytu BioScience Inc Earnings Release - Time Not Supplied
us.rd.yahoo.com - February 9 at 3:55 PM
finance.yahoo.com logoAytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits …
finance.yahoo.com - February 1 at 8:58 PM
us.rd.yahoo.com logoAytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men
us.rd.yahoo.com - February 1 at 3:57 PM
us.rd.yahoo.com logoAytu BioScience to Provide Fiscal Second Quarter 2017 Business Update
us.rd.yahoo.com - January 31 at 4:01 PM
finance.yahoo.com logoAytu BioScience to Present at Noble Capital Markets' 13th Annual Investor Conference
finance.yahoo.com - January 24 at 4:19 PM
finance.yahoo.com logoAytu BioScience Announces Two Presentations Highlighting Benefits of Natesto® (Testosterone) Nasal Gel …
finance.yahoo.com - January 18 at 9:27 PM
us.rd.yahoo.com logoAytu BioScience Announces Two Presentations Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting
us.rd.yahoo.com - January 18 at 4:26 PM
us.rd.yahoo.com logoAytu BioScience to Present at Biotech Showcase 2017 Investor Conference
us.rd.yahoo.com - January 4 at 3:53 PM
prnewswire.com logoAytu BioScience Launches Asian Distribution Network for Company's MiOXSYS® System for Male Infertility
www.prnewswire.com - December 15 at 3:37 PM
finance.yahoo.com logoAytu BioScience to Present at 9th Annual LD Micro Investor Conference
finance.yahoo.com - December 1 at 3:49 PM
us.rd.yahoo.com logo8:08 am Aytu BioScience announced findings that demonstrated 'significant' clinical improvements in erectile function and mood in hypogonadal men treated with Natesto nasal testosterone gel
us.rd.yahoo.com - November 30 at 3:47 PM
finance.yahoo.com logoAytu BioScience Announces Study Findings Demonstrating Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with Natesto® Nasal Testosterone Gel
finance.yahoo.com - November 30 at 8:13 AM
us.rd.yahoo.com logoAytu BioScience to Webcast, Live, at VirtualInvestorConferences.com December 1
us.rd.yahoo.com - November 29 at 5:41 PM

Social

Chart

Aytu Bioscience (AYTU) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff